SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this "Agreement")

is dated as of September [ ], 2025, between Predictive Oncology, Inc., a Delaware corporation (the "Company"),

and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser"

and collectively, the "Purchasers").

WHEREAS, subject to the terms and conditions set forth

in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and the rules and regulations promulgated

thereunder (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder, the Company desires to issue

and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Shares (as hereinafter

defined) and/or Pre-Funded Warrants (as hereinafter defined) of the Company as more fully described in this Agreement (the "Offering");

WHEREAS, contemporaneously with the sale of the securities

hereunder, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit A

(the "Registration Rights Agreement"), pursuant to which the Company will agree to provide certain registration rights

in respect of the Shares (as hereinafter defined) and the Pre-Funded Warrant Shares (as hereinafter defined) under the Securities Act,

and the rules and regulations promulgated thereunder, and applicable state securities laws;

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants

contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,

the Company and each Purchaser agree as follows:

1.1 Definitions. In addition to the terms defined

elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:

"Acquiring Person" shall have the

meaning ascribed to such term in Section 4.5.

"Action" shall have the meaning

ascribed to such term in Section 3.1(j).

"Affiliate" means any Person that,

directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such

terms are used in and construed under Rule 405 under the Securities Act.

"Asset Management Agreement" means

the Asset Management Agreement between the Company and DNA, to be executed on or prior to the Closing Date.

"Board of Directors" means the board

of directors of the Company.

"Business Day" means any day other

than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;

provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to

"stay at home", "shelter-in-place", "non-essential employee" or any other similar orders or restrictions

or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer

systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.

"Commission" means the United States

Securities and Exchange Commission.

"Closing Date" means the Trading

Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent

to (i) the Purchasers' obligations to pay the Subscription Amount and (ii) the Company's obligations to deliver the Securities

purchased at the Closing, in each case, have been satisfied or waived.

"Common Stock" means the common

stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified

"Common Stock Equivalents" means

any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,

without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable

or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

"Company Counsel" means DLA Piper

"Disclosure Time" means, (i) if

this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City

time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed

as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m.

(New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed

as to an earlier time by the Placement Agent.

"DNA" means DNA Holdings Venture,

"Effective Date" means the earliest

of the date that (a) the initial Registration Statement registering for resale all Shares and Pre-Funded Warrant Shares has been declared

effective by the Commission, (b) all of the Shares and Pre-Funded Warrant Shares have been sold pursuant to Rule 144 or may be sold pursuant

to Rule 144 without the requirement for the Company to be in compliance with the current public information requirement of Rule 144 and

without volume or manner-of-sale restrictions, (c) following the one year anniversary of the Closing Date, or (d) all of the Shares and

Pre-Funded Warrant Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without volume

or manner-of-sale restrictions.

"Escrow Agent" means Continental

Stock Transfer & Trust Company, with offices at 1 State Street, 30th Floor, New York, New York 10004.

"Escrow Agreement" means the escrow

agreement in the form of Exhibit D attached hereto, to be entered into, by and among the Company, the Escrow Agent and the Placement

Agent pursuant to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to be released to the Company subject

to the satisfaction or waiver of the Closing conditions set forth in Sections 2.2 and 2.3 herein.

"Evaluation Date" shall have the

meaning ascribed to such term in Section 3.1(s).

"Exchange Act" means the Securities

Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"Exempt Issuance" means the issuance

(a) of shares of Common Stock, options, restricted stock units or other equity awards, to employees, consultants, officers or directors

of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee members

of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services

rendered to the Company, (b) of securities upon the exercise or exchange or conversion of any Securities issued hereunder and/or securities

(including options, rights or warrants) exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding

on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number

of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection

with stock splits or combinations) or to extend the term of such securities; (c) of the Strategic Advisor Warrants and the shares of Common

Stock underlying the Strategic Advisor Warrants (d) of securities issued pursuant to acquisitions or strategic transactions approved by

a majority of the disinterested directors of the Company, provided that such securities are issued as "restricted securities"

(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection

therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to

the equityholders of a Person) which is, itself or through its Subsidiaries, an operating company or an owner of an asset in a business

synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,

but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity

whose primary business is investing in securities; (e) warrants to purchase Common Stock to be issued to the Placement Agent (or its designees)

(the "Placement Agent Warrants") on or about the date hereof and the shares of Common Stock underlying the Placement

Agent Warrants, and (f) shares of Common Stock issued pursuant to any New Sales Agreement or any at-the market offering sales agreement

with the Placement Agent, equity line of credit or similar agreement that is in effect as of the Closing (an "Existing Sales

"Existing Purchase Agreement" means

the Securities Purchase Agreement by and between the Company and the Existing Stockholder dated as of August 26, 2025.

"Existing Stockholder" means DNA.

"FCPA" means the Foreign Corrupt

Practices Act of 1977, as amended.

"GAAP" shall have the meaning ascribed